Gastrointestinal stromal tumors

John R. Zalcberg, Desmond Yip, Christine Hemmings, Bruce Mann, Charles Blanke

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development of effective targeted therapies such imatinib mesylate in a relatively short period of time for both the advanced and adjuvant settings. Sunitinib, a multikinase inhibitor, has also been proven as second line therapy and other biological agents such as nilotinib and sorafenib are in clinical testing. Mutational analysis of GIST contributes predictive and prognostic information helping to guide biological therapies. The multidisciplinary management of GIST has also challenged some traditional oncological paradigms.

Original languageEnglish (US)
Title of host publicationGastrointestinal Oncology: A Practical Guide
PublisherSpringer Berlin Heidelberg
Pages139-172
Number of pages34
ISBN (Print)9783642133053
DOIs
StatePublished - 2011
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Biological Therapy
Biological Factors
Gastrointestinal Tract
Neoplasms
Radiotherapy
Therapeutics
Drug Therapy
Mutation
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zalcberg, J. R., Yip, D., Hemmings, C., Mann, B., & Blanke, C. (2011). Gastrointestinal stromal tumors. In Gastrointestinal Oncology: A Practical Guide (pp. 139-172). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-13306-0_6

Gastrointestinal stromal tumors. / Zalcberg, John R.; Yip, Desmond; Hemmings, Christine; Mann, Bruce; Blanke, Charles.

Gastrointestinal Oncology: A Practical Guide. Springer Berlin Heidelberg, 2011. p. 139-172.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zalcberg, JR, Yip, D, Hemmings, C, Mann, B & Blanke, C 2011, Gastrointestinal stromal tumors. in Gastrointestinal Oncology: A Practical Guide. Springer Berlin Heidelberg, pp. 139-172. https://doi.org/10.1007/978-3-642-13306-0_6
Zalcberg JR, Yip D, Hemmings C, Mann B, Blanke C. Gastrointestinal stromal tumors. In Gastrointestinal Oncology: A Practical Guide. Springer Berlin Heidelberg. 2011. p. 139-172 https://doi.org/10.1007/978-3-642-13306-0_6
Zalcberg, John R. ; Yip, Desmond ; Hemmings, Christine ; Mann, Bruce ; Blanke, Charles. / Gastrointestinal stromal tumors. Gastrointestinal Oncology: A Practical Guide. Springer Berlin Heidelberg, 2011. pp. 139-172
@inbook{a55f2ec3c0544f729de5478131850e4a,
title = "Gastrointestinal stromal tumors",
abstract = "Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development of effective targeted therapies such imatinib mesylate in a relatively short period of time for both the advanced and adjuvant settings. Sunitinib, a multikinase inhibitor, has also been proven as second line therapy and other biological agents such as nilotinib and sorafenib are in clinical testing. Mutational analysis of GIST contributes predictive and prognostic information helping to guide biological therapies. The multidisciplinary management of GIST has also challenged some traditional oncological paradigms.",
author = "Zalcberg, {John R.} and Desmond Yip and Christine Hemmings and Bruce Mann and Charles Blanke",
year = "2011",
doi = "10.1007/978-3-642-13306-0_6",
language = "English (US)",
isbn = "9783642133053",
pages = "139--172",
booktitle = "Gastrointestinal Oncology: A Practical Guide",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Gastrointestinal stromal tumors

AU - Zalcberg, John R.

AU - Yip, Desmond

AU - Hemmings, Christine

AU - Mann, Bruce

AU - Blanke, Charles

PY - 2011

Y1 - 2011

N2 - Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development of effective targeted therapies such imatinib mesylate in a relatively short period of time for both the advanced and adjuvant settings. Sunitinib, a multikinase inhibitor, has also been proven as second line therapy and other biological agents such as nilotinib and sorafenib are in clinical testing. Mutational analysis of GIST contributes predictive and prognostic information helping to guide biological therapies. The multidisciplinary management of GIST has also challenged some traditional oncological paradigms.

AB - Gastrointestinal stromal tumors (GISTs) though relatively rare are the most common mesenchymal tumors of the gastrointestinal tract. In the past treatment was mainly confined to surgical resection. These tumors are relatively resistant to chemotherapy and radiotherapy. Recent understanding of pathogenesis especially the role of gain of function KIT gene mutations has enabled the rationale development of effective targeted therapies such imatinib mesylate in a relatively short period of time for both the advanced and adjuvant settings. Sunitinib, a multikinase inhibitor, has also been proven as second line therapy and other biological agents such as nilotinib and sorafenib are in clinical testing. Mutational analysis of GIST contributes predictive and prognostic information helping to guide biological therapies. The multidisciplinary management of GIST has also challenged some traditional oncological paradigms.

UR - http://www.scopus.com/inward/record.url?scp=84892102051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892102051&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-13306-0_6

DO - 10.1007/978-3-642-13306-0_6

M3 - Chapter

AN - SCOPUS:84892102051

SN - 9783642133053

SP - 139

EP - 172

BT - Gastrointestinal Oncology: A Practical Guide

PB - Springer Berlin Heidelberg

ER -